Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Case report

Spontaneous regression of bone metastasis from renal cell carcinoma; A case report

Authors: Takahiro Nakajima, Makoto Suzuki, Soichiro Ando, Tomohiko Iida, Akinobu Araki, Takehiko Fujisawa, Hideki Kimura

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Spontaneous regression of metastatic renal cell carcinoma is rarely observed.

Case presentation

Metastatic renal cell carcinoma was identified in a 70-year-old male using computed tomography-guided percutaneous needle biopsy. Two months after the diagnosis, a partial resection of the sternal bone was performed. Pathological examination revealed granulated tissue with bleeding and necrosis but no carcinogenic cells.

Conclusion

We report a pathologically identified case in which a sternal bone metastasis that was noticed two years after radical nephrectomy regressed completely and spontaneously.
Appendix
Available only for authorised users
Literature
1.
Bumpus HC: The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy. J Urol. 1928, 20: 185-
2.
Snow RM, Schellhammer PF: Spontaneous regression of metastatic renal cell carcinoma. Urology. 1982, 20: 177-181. 10.1016/0090-4295(82)90356-9.CrossRefPubMed
3.
4.
Lokich J: Spontaneous regression of metastatic renal cancer: case report and literature review. Am J Clin Oncol. 1997, 20: 416-418. 10.1097/00000421-199708000-00020.CrossRefPubMed
5.
Fairlamb DJ: Spontaneous regression of metastases of renal cancer: A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer. 1981, 47: 2102-2106.CrossRefPubMed
6.
Ricardo F, Sanchez O, Nizar T, Kamran A, Chiristopher GW: Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of the primary tumor: An in situ tumor vaccine?. J Urol. 2004, 170: 178-179.
7.
Ljungberg B, Alamdari FI, Rasmuson T, Roos G: Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU. 1999, 84: 405-411. 10.1046/j.1464-410x.1999.00202.x.CrossRef
8.
Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Perol D, Lasset C: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol. 2002, 13: 1460-1468. 10.1093/annonc/mdf257.CrossRefPubMed
9.
Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998, 338: 1272-1278. 10.1056/NEJM199804303381805.CrossRefPubMed
Metadata
Title
Spontaneous regression of bone metastasis from renal cell carcinoma; A case report
Authors
Takahiro Nakajima
Makoto Suzuki
Soichiro Ando
Tomohiko Iida
Akinobu Araki
Takehiko Fujisawa
Hideki Kimura
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-11

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy

Research article

On systems and control approaches to therapeutic gain

Research article

A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer

Research article

The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis

Research article

Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)

Research article

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits